SLE合并症独特模式通过持续疾病活动和延迟激素减量阻碍治疗目标达成
该多中心回顾性队列纳入347例基线时接受治疗强化的活动性SLE患者,中位随访5年。合并症负担高且纵向增加,与DORIS和LLDAS达成率降低相关,肥胖、血脂异常、高血压、卒中、抑郁、纤维肌痛和甲状腺疾病影响最大。合并症通过持续疾病活动和延迟糖皮质激素减量独立阻碍目标达成,并与更多器官损伤累积相关。
要点
- SLE患者合并症负担高且随时间增加,与DORIS和LLDAS达成率降低相关。
- 肥胖、血脂异常、高血压、卒中、抑郁、纤维肌痛和甲状腺疾病影响最大。
- 合并症患者持续疾病活动和激素减量延迟,且器官损伤累积更多。
核心结论
- SLE患者合并症负担高,其独特模式与治疗目标达成率降低相关。
- 合并症通过持续疾病活动和延迟糖皮质激素减量独立阻碍DORIS/LLDAS达成。
- 合并症与更多器官损伤累积相关,持续DORIS/LLDAS可减弱该关联。
研究设计与样本
- 多中心回顾性队列研究,纳入347例基线时接受治疗强化的活动性SLE患者。
- 监测140种合并症、疾病活动度、治疗和器官损伤,中位随访5年。
- 采用混合效应模型评估合并症与DORIS/LLDAS的关系,随机森林排序合并症影响。
主要发现
- 患者中位年龄46岁、中位病程9个月,合并症负担高且纵向增加。
- 合并症与DORIS达成率降低相关(ORs: 0.77-0.87, p<0.05),与LLDAS降低相关(ORs: 0.74-0.91, p<0.01)。
- 肥胖、血脂异常、高血压、卒中、抑郁、纤维肌痛和甲状腺疾病为影响最大的合并症。
- 存在≥1种上述合并症者(n=238 [68.6%])达成持久DORIS/LLDAS(≥50%时间)的可能性降低55-60%。
- 合并症与更多器官损伤累积相关(IRR: 1.38, 95% CI 1.11 to 1.71),持续DORIS/LLDAS患者中该关联减弱。
关键数值与推荐
- DORIS达成率降低的ORs范围为0.77-0.87(p<0.05)。
- LLDAS达成率降低的ORs范围为0.74-0.91(p<0.01)。
- 存在≥1种关键合并症者持久DORIS/LLDAS达成可能性降低55-60%。
- 器官损伤累积的IRR为1.38(95% CI 1.11 to 1.71)。
临床怎么用
- 对SLE患者应警惕高合并症负担,尤其肥胖、血脂异常、高血压、卒中、抑郁、纤维肌痛和甲状腺疾病。
- 合并症患者需更 vigilant 监测和治疗调整,以维持疾病控制并防止损伤。
- 应关注持续疾病活动和延迟糖皮质激素减量对目标达成的影响。
局限性
- 回顾性队列设计可能引入偏倚。
- 中位随访5年,长期影响需进一步验证。
- 合并症与目标达成的因果关系需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many patients fail to achieve them, underscoring the need to identify contributing barriers. We explored whether comorbidities-some of which share genetic risk with lupus-and their specific patterns influence target accomplishment. METHODS: Retrospective cohort of 347 patients with active SLE receiving treatment intensification at inclusion. Comorbidities (n=140), disease activity, treatments and organ damage were monitored (median follow-up 5 years). Mixed-effects assessed relationships between comorbidities and definitions of remission in SLE/lupus low disease activity state (DORIS/LLDAS). Random forests ranked comorbidities according to the strength of associations. RESULTS: Despite the relatively young age (median 46 years) and short disease duration (median 9 months), patients with SLE exhibited high comorbidity burden (comorbidities count, Rheumatic Disease Comorbidity Index, Elixhauser, Charlson), which increased longitudinally and was associated with reduced attainment of DORIS (ORs: 0.77-0.87, p<0.05) and LLDAS (ORs: 0.74-0.91, p<0.01). Obesity, dyslipidaemia, hypertension, stroke, depression, fibromyalgia and thyroid disorders emerged as the most influential. Presence of ≥1 of these conditions (n=238 [68.6%]) was linked to 55-60% lower likelihood of durable DORIS/LLDAS (≥50% time). Marginal structural models (MSMs) confirmed an independent comorbidities-targets association, regardless of prior achievement, explained by smouldering activity and delayed glucocorticoid tapering. While immunosuppressant/biologic use was comparable, comorbid patients received lower glucocorticoid doses during high disease activity. Comorbidities were also associated with greater damage accrual (IRR: 1.38, 95% CI 1.11 to 1.71), attenuated in patients with sustained DORIS/LLDAS. CONCLUSIONS: Patients with SLE manifest high comorbidity burden, with distinct patterns linked to reduced target attainment. In these patients, vigilant monitoring and treatment adjustments are essential to sustain disease control and prevent damage.
引用
- Nikoloudaki M, Barmparis GD, Pitsigavdaki S, et al. Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study. RMD Open. 2026. PMID: 41781160. doi:10.1136/rmdopen-2025-006424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。